Compounding Pharmacy Market Research Report 2022 Global Analysis, Opportunities and Forecast to 2031

The growing number of patients visiting doctors to seek medical care for chronic conditions and the high need for prescription drugs are driving an expanding global market for compound pharmacies. Compound pharmacists provide personalized medications to patients who cannot get results from taking commercially accessible pharmaceuticals.

The demand for personalized hormone replacement therapies has increased in the recent past as people have become more aware of important health functions such as breast and bone health, erectile longevity, osteoporosis, mood swings, hot flashes , acute levels of depression, etc.

As a result, dosage requirements for specific custom solutions have driven the demand for hormones such as progesterone after hysterectomy, testosterone replacement, hormones that treat infertility, etc. These therapies are expensive and in high demand, due to the rapid growth of lifestyle-related diseases in the young population due to lifestyle changes and increased stress levels.

Key players are focusing on strengthening their position by partnering with local producers and acquisitions to improve their sales. Additionally, companies are targeting North America, Asia Pacific, and Europe by adopting R&D and partnerships in the market.

• In November 2020, B. Braun Melsungen AG and Grifols entered into a strategic partnership to improve the production of combination drugs and services for hospitals. Grifols is a leading manufacturer of plasma-derived medicines and has compounding centers in the United States
• In February 2016, PharMEDium Services, LLC announced an exclusive source agreement with Premier, Inc. to provide a broad range of services used for pain management, operating room anesthesia, critical care, nerve block and labor and delivery.

Such developments not only strengthen a company’s existing portfolio, but also help increase its presence regionally and globally.

Company profiles:

• Fagron
• Fresenius Kabi AG
• Pharmaceutical Services, LLC
• Solutions for institutional pharmacies
• Cantrell pharmaceutical company
• Lorraine Pharmacy
• B.Braun Melsungen AG

 

 

Methodology Request @  https://www.persistencemarketresearch.com/methodology/5270

Key points of the market study

• By product, oral medicines are expected to hold a high share of 43.5% in 2021, expanding to 9.6% CAGR during the forecast period.
• By application, adult drugs will maintain a high share of 53.3% in 2021, expanding to 9.5% CAGR during the forecast period.
• In terms of therapeutic area, hormone replacement therapy represents a market share of 63.5% in 2021.
• By region, North America held the largest share of 66.3% in 2021, due to the emergence of new compounding pharmacies in North America to meet the growing need for specialized care and hard drugs.

“Increased drug drought in levels of drug demand worldwide, rising cost of branded prescription equivalents and inadequate drug accessibility are expected to drive demand for composite pharmacies,”  says an analyst . by Persistence Market Research.

Who is winning?

Some of the leading compounding pharmacy manufacturers are focusing on product approvals, acquisitions, mergers, collaborations and partnerships for global expansion goals, thereby strengthening their market presence.

• On May 27, 2020, the U.S. FDA accepted Fresenius Kabi’s first biosimilar regulatory request for MSB11455, a pegfilgrastim biosimilar candidate, for review.
• In April 2018, Fagron acquired Humco, a developer, manufacturer and supplier of patented delivery vehicles and branded pharmaceuticals in the United States.
• In September 2015, Lorraine’s pharmacy received $ 53.9 million in funding from the United States government to gain FDA approval for its ReCell product, an autologous cell harvesting device.
• In mid-2015, Fagron merged with AnazaoHealth Corporation, which specializes in custom nuclear, pain reliever and intrathecal drugs.

Key market players covered in the research by Persistence Market Research include Fagron, Fresenius Kabi AG, PharMEDium Services, LLC, Institutional Pharmacy Solutions, Cantrell Drug Company, Lorraine’s Pharmacy, and B. Braun Melsungen AG Company.

What does the report cover?

Persistence Market Research offers a unique perspective and actionable insights into compounding pharmacies in its latest study, presenting the 2016-2020 historical demand assessment and 2021-2031 projections.

The study provides compelling insights into the composite pharmacy market. The market is segmented by product (oral medicines (capsules, tablets, mixtures, lollipops, lozenges), topical medicines (gels, ointments, creams, lotions, mouthwashes and suppositories)), application (adult medicines, medicines for veterinary, children’s and geriatric medicines) and therapeutic area (pain management and hormone replacement therapy), in five major regions of the world.

Access the full report @  https://www.persistencemarketresearch.com/checkout/5270